A Phase 1/2, Randomized Clinical Study to Assess the Safety and Efficacy of Sirolimus in Patients With Newly Diagnosed, Treatment-Naive Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Latest Information Update: 19 May 2014
At a glance
- Drugs Sirolimus (Primary)
- Indications Age-related macular degeneration; Choroidal neovascularisation
- Focus Therapeutic Use
- Sponsors Santen Pharmaceutical
Most Recent Events
- 19 May 2014 New trial record